FDAsafety guidance65% confidence
FDA AP — BREZTRI AEROSPHERE (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (asthma) as Breztri Gains US Approval as First Triple Therapy for Asthma.
Regulatory Analysis
Application NDA212122. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUDESONIDE, FORMOTEROL FUMARATE, GLYCOPYRROLATE.
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Asthma
Related signal: Breztri Gains US Approval as First Triple Therapy for Asthma